Pharmafile Logo
Pharmafocus logo
Advanced Search

AstraZeneca

Showing 15 posts of 785 posts found.

astrazeneca_plaque

AstraZeneca sells Amrimidx and Casodex European rights to Juvisé Pharmaceuticals

December 20, 2019
Medical Communications AstraZeneca, Cancer, Juvise, breast cancer, prostate cancer

AstraZeneca has announced that it has agreed to sell the rights to Arimidex (anastrozole) and Casodex (bicalutamide) in Europe, as …

News
311334432_ec96cf3d30_b

AstraZeneca Vietnam obtains license to import pharmaceuticals

December 19, 2019
Business Services AstraZeneca, AstraZeneca Vietnam, Vietnamese, vietnam

AstraZeneca Vietnam Co. Ltd becomes only the second multinational company in the country to obtain a license to import pharmaceuticals. …

News
5204602349_c87b204860_b

FDA advisory committee approves the use of Lynparza in pancreatic cancer

December 18, 2019
Research and Development AstraZeneca, Cancer, Merck, Pancreatic cancer, lynparza

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of AstraZeneca and Merck’s Lynparza (olaparib) to treat pancreatic …

News
china-1081714_1920

China approves AstraZeneca’s Imfinzi for advanced non-small cell lung cancer

December 12, 2019
Sales and Marketing AstraZeneca, Imfinzi, pharma

AstraZeneca’s Imfinzi (durvalumab) is set to be made available in China after the country’s National Medical Products Administration (NMPA) decided …

News

AstraZeneca’s trial of leukaemia drug Calquence yields positive results

December 9, 2019
Sales and Marketing AstraZeneca, Calquence, leukaemia, phase 3

AstraZeneca confirmed it had recorded positive results from its Phase 3 trial of Calquence plus obinutuzumab in leukaemia. The trial …

News
astrazeneca_plaque

AstraZeneca sells US/Canada rights for Seroquel for $41 million to “focus on main therapy areas”

December 3, 2019
Manufacturing and Production, Sales and Marketing AstraZeneca, pharma

AstraZeneca has announced its intention to jettison the rights to two non-core drugs in the US and Canada in order …

News

FDA gives priority review for AstraZeneca’s Imfinzi

November 29, 2019
Medical Communications AstraZeneca, Cancer, FDA, Imfinzi, lung cancer

The FDA has granted a priority review of AstraZeneca’s cancer treatment drug Imfinzi (durvalumab) for treatment of patients with untreated …

News
34778112_496a002303_b

Drugmakers cut prices by 61% to get on Chinese reimbursement list

November 28, 2019
Manufacturing and Production AstraZeneca, China, China National Reimbursement Scheme, Novartis, Roche Holding

AstraZeneca and Roche Holding are among a number of drugmakers to cut their prices in order to get on China’s …

News
astrazeneca_sign_sky

AstraZeneca’s Qtrilment scores European authorisation in type 2 diabetes

November 15, 2019
Medical Communications, Sales and Marketing AstraZeneca, EU, Europe, Qtrilmet, diabetes, pharma, type 2 diabetes

Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) has secured approval in Europe, its manufacturer AstraZeneca has revealed, as a therapy to …

News
astrazeneca_sign_sky

AstraZeneca’s roxadustat boosts haemoglobin levels in two Phase 3 trials

November 8, 2019
Medical Communications, Research and Development AstraZeneca, pharma, roxadustat

AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient haemoglobin (Hb) …

News
astrazeneca_plaque_42

AstraZeneca reveals three-pronged “large-scale” R&D initiatives in China

November 7, 2019
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, China

AstraZeneca has doubled down on its commitment to the Chinese region with the announcement of three “large-scale initiatives” in the …

News

AstraZeneca’s Imfinzi triple combo beats chemo in treatment-naive metastatic lung cancer

October 29, 2019
Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, NSCLC, lung cancer, pharma

AstraZeneca has unveiled positive new Phase 3 data for the combination of Imfinzi (durvalumab) and anti-CTLA4 antibody tremelimumab with chemotherapy …

News
astrazeneca_building_white

FDA approves single-use auto-injector form of IL-5 inhibitor Fasenra

October 4, 2019
Medical Communications, Sales and Marketing AstraZeneca, FDA, Fasenra, pharma

AstraZeneca is celebrating as the FDA announced the approval of its IL-5 inhibitor Fasenra  (benralizumab) in a pre-filled, single-use auto-injector …

News
astrazeneca_building_white

AZ’s Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer

September 30, 2019
Research and Development, Sales and Marketing AstraZeneca, Cancer, ESMO 2019, Tagrisso, lung cancer, pharma

AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new …

News

New agreement gives AstraZeneca full responsibility for Linzess in China

September 18, 2019
Research and Development AstraZeneca, IBS-C, Linzess

AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals in China for Linzess (linaclotide), a first-in-class new treatment for patients …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025